Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $107.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $28.00K, a 64.56% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $79.00K, a 93.79% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $635.00K, a 69.79% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $137.00K, a 93.89% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.12M, a 73.48% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $8.01M, a 126.67% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $3.53M, a 42.41% decline from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $6.13M, a 79.47% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $107.00K 10-Q · filed 2026-08-10 | $742.00K derived: sum of 3 quarters · filed 2026-08-10 | $879.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $79.00K 10-Q · filed 2026-05-11 | $714.00K derived: sum of 2 quarters · filed 2026-05-11 | $851.00K derived: sum of 3 quarters · filed 2026-05-11 | $930.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $635.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $772.00K derived: sum of 2 quarters · filed 2026-03-03 | $851.00K derived: sum of 3 quarters · filed 2026-08-10 | $2.12M 10-K · filed 2026-03-03 |
| 2025-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $216.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.49M 10-Q · filed 2025-11-06 | $1.86M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.35M 10-Q · filed 2026-08-10 | $1.73M derived: sum of 3 quarters · filed 2026-08-10 | $3.97M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-11 | $1.65M derived: sum of 2 quarters · filed 2026-05-11 | $3.89M derived: sum of 3 quarters · filed 2026-05-11 | $5.69M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.62M derived: sum of 2 quarters · filed 2026-03-03 | $4.42M derived: sum of 3 quarters · filed 2026-03-03 | $8.01M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.05M derived: sum of 2 quarters · filed 2025-11-06 | $7.63M 10-Q · filed 2025-11-06 | $8.74M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $5.39M 10-Q · filed 2025-08-11 | $6.50M derived: sum of 3 quarters · filed 2026-03-03 | $6.87M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $3.59M 10-Q · filed 2025-05-08 | $4.69M derived: sum of 2 quarters · filed 2026-03-03 | $5.06M derived: sum of 3 quarters · filed 2026-03-03 | $6.56M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $1.47M derived: sum of 2 quarters · filed 2026-03-03 | $2.97M derived: sum of 3 quarters · filed 2026-03-03 | $3.53M 10-K · filed 2026-03-03 |
| 2023-09-30 | $368.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $1.86M derived: sum of 2 quarters · filed 2024-11-08 | $2.43M 10-Q · filed 2024-11-08 | $2.71M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.06M 10-Q · filed 2024-08-08 | $2.34M derived: sum of 3 quarters · filed 2025-03-17 | $4.27M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $561.00K 10-Q · filed 2024-05-08 | $840.00K derived: sum of 2 quarters · filed 2025-03-17 | $2.78M derived: sum of 3 quarters · filed 2025-03-17 | $4.05M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.22M derived: sum of 2 quarters · filed 2025-03-17 | $3.49M derived: sum of 3 quarters · filed 2025-03-17 | $6.13M 10-K · filed 2025-03-17 |
| 2022-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $3.21M derived: sum of 2 quarters · filed 2023-11-08 | $5.85M 10-Q · filed 2023-11-08 | $13.55M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.92M 10-Q · filed 2023-08-03 | $11.61M derived: sum of 3 quarters · filed 2024-02-29 | $24.33M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $2.64M 10-Q · filed 2023-05-08 | $10.34M derived: sum of 2 quarters · filed 2024-02-29 | $23.06M derived: sum of 3 quarters · filed 2024-02-29 | $28.76M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $7.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $20.42M derived: sum of 2 quarters · filed 2024-02-29 | $26.12M derived: sum of 3 quarters · filed 2024-02-29 | $29.88M 10-K · filed 2024-02-29 |
| 2021-09-30 | $12.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $18.42M derived: sum of 2 quarters · filed 2022-11-02 | $22.19M 10-Q · filed 2022-11-02 | $22.59M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $5.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.46M 10-Q · filed 2022-08-04 | $9.86M derived: sum of 3 quarters · filed 2023-03-16 | $10.05M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $3.76M 10-Q · filed 2022-05-10 | $4.16M derived: sum of 2 quarters · filed 2023-03-16 | $4.35M derived: sum of 3 quarters · filed 2023-03-16 | $4.37M derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $582.00K derived: sum of 2 quarters · filed 2023-03-16 | $605.00K derived: sum of 3 quarters · filed 2023-03-16 | $605.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $182.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $205.00K derived: sum of 2 quarters · filed 2021-11-08 | $205.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $23.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $25.00K 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |